Australian Particle Therapy Clinical Quality Registry (ASPIRE) is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy.

None listed

This is an observational, longitudinal registry of paediatric, adolescent, young adult (AYA) and rare adult tumour patients from a select group of tumour streams treated with radiotherapy. The registry is designed to describe the patterns of care for patients receiving photon versus proton radiation treatment. Who is it for? You may be eligible for this study if you are receiving radiotherapy for cancers of the following types: Base of Skull Meningioma, Chordoma, Chondrosarcoma, Tumour of the vertebral column or bony pelvis, Chordoma, Chondrosarcoma, Osteosarcoma, Ewing’s sarcoma of pelvis, Adenoid cystic carcinoma of the salivary or lacrimal gland, CNS, Medulloblastoma, Ependymoma, Glioma, Astrocytoma, Orbit, including retinoblastoma, Retinoblastoma, Axial skeleton or close proximity to axial skeleton, including bone or soft tissue sarcoma Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma of axial skeleton, Craniopharyngioma, Intracranial germ cell tumour, Neuroblastoma, or Nephroblastoma Study details There are no clinical interventions required for participants enrolled onto the registry. All enrolled participants will receive treatment, and follow-up care as pre-determined by their treating clinician, in accordance with the standard of care at the treating institution. All treatment interventions that participants receive, and all outcomes will be recorded on the registry database from the patient medical record. It is hoped that the development of this registry will assist in describing the long-term effects and disease control outcomes for patients having radiotherapy as part of their cancer treatment.